OREANDA-NEWS. OJSC Pharmacy Chain 36.6 [RTS: APTK; MICEX: RU14APTK1007] - the leading Russian pharmaceutical retailer announces 1H 2013 financial results prepared in accordance with the International Financial Reporting Standards (unaudited).

SALES:

Consolidated sales from ongoing operations reached RUR 9 389 mln in 1H 2013 which is a decrease of 14%;

Net[1] sales in the retail pharmacy segment reached RUR 6 690 mln which is a decrease of 10%;

As of the end of 1H 2013 Pharmacy Chain 36.6 operated 737 pharmacies in 24 regions;

During 1H 2013 10 stores were opened organically and 115 stores were closed. As of the end of 1H 2013 Pharmacy Chain 36.6 operated 8 stand-alone optical outlets and 25 additional optical departments within pharmacies.

PROFIT:

Consolidated gross profit in 1H 2013 reached RUR 3 833 mln which is a decrease of 17%;

Gross profit of the retail pharmacy segment reached in 1H 2013 RUR 2 200 mln versus 2 205 in 1H 2012. The gross profit margin in the retail segment in 1H 2013 increased by 3 points and reached 33%;

The Company's consolidated Operating profit[2] reached RUR 155 mln which is a decrease of 79% in y-o-y terms. Consolidated selling, general and administrative expenses in 1H 2013 decreased by 5% and reached RUR 3 678 mln;

The retail pharmacy segment Operating loss[3] in 1H 2013 reached RUR 512 mln versus RUR 281 mln in 1H 2012. Retail selling, general and administrative expenses equaled to RUR 2 712 mln;

Consolidated Net loss in 1H 2013 reached RUR 926 mln versus RUR 331 mln in 1H 2012.

FINANCIAL DEBT AND INVESTMENTS

Company's Net Debt (deducting the remaining monetary funds) equaled to RUR 10 627 mln;

As of the end of 1H 2013 consolidated financial debt reached RUR 11. Whereas the retail pharmacy debt equaled to RUR 9 184 mln, Veropharm's debt reached RUR 2 162 mln as of the end of 1H 2013;

Consolidated finance costs in 1H 2013 reached RUR 861 mln;

Consolidated investments in fixed and intangible assets in 1H 2013 reached RUR 1 652 mln, out of which retail investments in opening new pharmacies and re-branding equaled to RUR 69 mln, Veropharm investments reached RUR 1 583 mln. Whereas the amount of RUR 1 190 mln has been assigned for modernization and equipment of the main production facilities.